Presentation is loading. Please wait.

Presentation is loading. Please wait.

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis  Alan Menter,

Published byMaria Júlia Jardim Gonçalves Modified over 6 years ago

Similar presentations

Presentation on theme: "Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis  Alan Menter,"— Presentation transcript:

1 Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis  Alan Menter, MD, Diamant Thaçi, MD, Kim A. Papp, MD, Jashin J. Wu, MD, Mareike Bereswill, MS, Henrique D. Teixeira, PhD, Simone Rubant, PhD, David A. Williams, MD  Journal of the American Academy of Dermatology  Volume 73, Issue 3, Pages e6 (September 2015) DOI: /j.jaad Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Registry design. Feeder trials included M (phase III, n = 1, June 2003), M (phase II, n = 1, June 2003), M (open-label extension trial [OLE], n = 195, May 2004; included the REVEAL, CHAMPION, M trials for which the number of patients was counted separately from the OLE's 195 patients), M (phase III REVEAL, n = 3, December 2004), M (phase III CHAMPION, n = 2, July 2005), M (phase III, n = 1, June 2006), M (BELIEVE, n = 75, November 2007), W (phase III PRIDE, n = 62, September 2007), M (phase III PROGRESS, n = 25, January 2008), and M (phase IV REACH, n = 23, August 2008). ∗Patients are followed up at regular office visits, at intervals as determined by routine clinical practice or as recommended by national guidelines. Enrolled patients are followed up for up to 10 years, including patients who discontinue adalimumab before 10 years of registry participation, during regular office visits that are determined by routine practice or national guidelines. Registry visits are conducted initially at 3 and 6 months postenrollment, then every 6 months for up to 10 years. †Study start dates are shown. Journal of the American Academy of Dermatology  , e6DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Kaplan-Meier plots: continuation on registry drug (A) and time to occurrence of first treatment-emergent adverse event (TEAE) of special interest (all-treated population) (B). CVA, Cerebrovascular accident; MI, myocardial infarction; NMSC, nonmelanoma skin cancer; TB, tuberculosis. Journal of the American Academy of Dermatology  , e6DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Standardized mortality, overall and by sex. PY, Patient-years of exposure. Journal of the American Academy of Dermatology  , e6DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Proportion of observed (not necessarily on drug at the time of this assessment) patients achieving Physician Global Assessment 0 or 1: all-treated and new-prescription populations (A) and new-prescription population (B) by presence or absence of psoriatic arthritis (PsA). n, Number of patients with Physician Global Assessment 0 or 1 at the respective visit; N, number of patients with data at the respective visit. Journal of the American Academy of Dermatology  , e6DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis  Alan Menter,"

Similar presentations

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment  Juul M.P.A.

Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment  Juul M.P.A.
Clavi syphilitici–an unusual presentation of syphilis

Clavi syphilitici–an unusual presentation of syphilis
Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial  Verena Wally,

Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial  Verena Wally,
A girl with a solitary red bulla

A girl with a solitary red bulla
Facial adenocarcinoma treated with intra-arterial chemotherapy

Facial adenocarcinoma treated with intra-arterial chemotherapy
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 
Psoriasis and suicidality: A systematic review and meta-analysis

Psoriasis and suicidality: A systematic review and meta-analysis
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment  Juul M.P.A.

Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment  Juul M.P.A.
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

Similar presentations

Ads by Google